Stockscreener 앱 받기
50.46
0.02%
0.010
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Jefferies Financial Group Inc. Purchases New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Akero Therapeutics Inc. Hits Price Floor — Bounce IncomingAccurate Technical Trend Reversal Picks Detected - metal.it
Using Python tools to backtest Akero Therapeutics Inc. strategiesValue Investing Checklist with Entry Signals - Newser
Ranking Akero Therapeutics Inc. among high performing stocks via toolsFree AI Screening for Swing Trade Picks - Newser
Akari Therapeutics Reports Q2 EPS $(0.86) vs. $(0.81) Last Year - AInvest
Why Akero Therapeutics Inc. is moving todaySwing Reversal Forecast Based on Patterns - Newser
Can you recover from losses in Akero Therapeutics Inc.High Probability Trade Plan with Indicators - Newser
Is Akero Therapeutics Inc. building a consolidation baseHigh Reward Investment Strategy for Beginners - Newser
Published on: 2025-08-09 06:15:43 - beatles.ru
Akero Therapeutics Q2 Loss Narrows by 6%, EFX Clinical Trials Progress - AInvest
Vivo Capital LLC Acquires Shares of 201,168 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
When is the best time to exit Akero Therapeutics Inc.Free AI-Powered Trade Planning with Indicators - Newser
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Akero Therapeutics Advances in MASH Treatment Development - TipRanks
What MACD and RSI say about Akero Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Efruxifermin Advancements in MASH Treatment - AInvest
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position - TipRanks
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Akero Therapeutics Keeps Analysts Optimistic Despite Larger Losses - Finimize
Akero Therapeutics shares fall 1.31% intraday after Q2 net loss widens. - AInvest
Akero Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akero (AKRO) Q2 Loss Narrows 6% - Nasdaq
Akero Therapeutics' Q2 2025 Financial Results and Business Update: A Deep Dive into Metabolic Disease Innovation and Shareholder Value - AInvest
Akero Therapeutics Q2 Net Loss Widens - MarketScreener
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Akero Therapeutics Q2 net income just shy of estimates, cash position strong - MarketScreener
Earnings Flash (AKRO) Akero Therapeutics Posts Q2 Net Loss $0.86 a Share, vs. FactSet Est of $0.96 Loss - MarketScreener
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
3 Top Artificial Intelligence (AI) Stocks Ready for a Bull Run - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
When is the best time to buy Akero Therapeutics Inc. stockFree Community Shared Smart Money Signals - Newser
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - The Globe and Mail
Insider Selling at Akero Therapeutics: A Cautionary Signal Amidst Promising Clinical Progress - AInvest
Akero therapeutics CSO Rolph sells $616,299 in stock By Investing.com - Investing.com Canada
Allianz Asset Management GmbH Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements - TipRanks
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero - TipRanks
Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating - Investing.com Canada
TD Cowen Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - Defense World
Envestnet Asset Management Inc. Buys 3,170 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Strong Analyst Buy Ratings - AInvest
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
TD Cowen Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $76 - 富途牛牛
Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential - Investing.com Canada
Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential - Investing.com Canada
Analysts Initiate Coverage on Akero Therapeutics, AeroVironment, Wave Life Sciences, Palvella Therapeutics, and WeRide Inc. - AInvest
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Published on: 2025-08-04 16:41:28 - metal.it
These Were the 2 Best-Performing Stocks in the Dow Jones Industrial Average in July 2025 - The Globe and Mail
TD Cowen Initiates Akero Therapeutics at Buy With $76 Price Target - MarketScreener
TD Asset Management Inc Grows Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
What is Akero Therapeutics Inc. company’s growth strategyBreakthrough capital growth - Jammu Links News
What makes Akero Therapeutics Inc. stock price move sharplyPhenomenal trading returns - Jammu Links News
Is it the right time to buy Akero Therapeutics Inc. stockBreakthrough investment results - Jammu Links News
Akero Therapeutics Inc. Stock Analysis and ForecastBreakthrough profit margins - Jammu Links News
0.24%
3.39%
자본화:
|
볼륨(24시간):